InSightec ExAblate cancer pain therapy:
This article was originally published in Clinica
InSightec can now expand the use of its magnetic resonance-guided focused ultrasound (MRgFUS) therapy from treatment of uterine fibroids to pain palliation of bone metastases. Its product, called ExAblate 2000, can alleviate pain, has the potential to lower reliance on analgesics and can provide patients with the opportunity for improved quality of life, the company said of the new indication. It is estimated that 100,000 people in Europe are diagnosed with bone metastases every year, said the Haifa, Israel-based firm.
You may also be interested in...
Topline results with AZD1222 have shown a lower efficacy rate than the Pfizer and Moderna vaccines, but a subgroup receiving a half-dose in their first injection showed a 90% efficacy result.
Krka’s bottom line continues to be stronger than usual, driven by a hike in sales and leaner cost base. Looking to 2021, however, management brought investors back down to earth.
The COVID-19 pandemic has triggered extraordinary levels of collaboration. But competition remains, and many newly created coalitions have yet to be stress tested.